Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6+
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
About this trial
Given the renewed focus on mastocytosis (recognized in Italy as a rare disease since 2018) and emerging clinical and immunogenetic knowledge, and considering the rarity of the disease and limited understanding of its progression, this observational study aims to analyze epidemiological, clinical, genetic, immunohistochemical, and laboratory characteristics of patients with mastocytosis. This will help expand knowledge about the disease and identify prognostic variables useful in developing a personalized therapeutic approach.
This registry aims to collect retrospective and prospective data on patients with cutaneous and systemic mastocytosis attending the Dermatology Unit at the IRCCS Fondazione Policlinico San Matteo.
This is a single-center longitudinal hospital registry including patients with cutaneous and systemic mastocytosis, collected retrospectively and prospectively to assess the clinical, serological, hematological, and molecular characteristics of patients with cutaneous and systemic mastocytosis and their correlation with specific outcomes such as disease variant (cutaneous or systemic), extent of skin involvement, and survival rate.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
All patients diagnosed with cutaneous or systemic mastocytosis attending the Dermatology Outpatient Clinics of the UOC Dermatology Unit Fondazione Policlinico San Matteo IRCCS Pavia will be eligible for inclusion in the registry.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 1 trial groupGroup A: patients diagnosed with cutaneous or systemic mastocytosis
Trial outcomes
Primary outcomes
1
Prevalence of the systemic disease variant in the examined population
The prevalence and the 95% exact binomial confidence interval will be presented
Time frame
January 2034Secondary outcomes
1
Association between clinical, serological, hematological, and molecular characteristics and the disease variant (cutaneous or systemic)
The association will be evaluated using a multivariate logistic model; the number of covariates will be limited by the number of systemic mastocytosis cases, maintaining a 1:10 ratio. The selection of covariates will be made a priori based on scientific knowledge. Odds ratios (OR) and their corresponding 95% confidence intervals (CI) will be reported. The model's discriminatory ability (area under the ROC curve) and its calibration (graphically) will be calculated
Time frame
January 20342
Association between family history and age of disease onset
The analysis will be performed using a multivariate logistic model
Time frame
January 20343
Survival rate in relation to the disease variant (cutaneous or systemic)
The survival rate will be reported as deaths per 100 person-years; the start date for follow-up will be the diagnosis of the disease. The groups will be compared using the log-rank test, and survival will be described using Kaplan-Meier curves. A Cox model will be used to derive the hazard ratio (HR) and the corresponding 95% confidence interval (CI). Harrell's C-statistic will be calculated to assess the model's discriminatory ability. Estimates will be adjusted, where possible, for potential confounding factors
Time frame
January 20344
Association between c-KIT mutation in blood and clinical characteristics of the patient
The analysis will be performed using a multivariate logistic model
Time frame
January 2034Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov